Introduction

Advances in joint care have expanded the options available to adults who want to protect a worn joint without resorting to replacement surgery. ChondroFiller is a Class III CE-marked type I collagen scaffold that is delivered as a non-surgical, ultrasound-guided outpatient injection — no theatre, no incision, no general anaesthetic. Once placed, the acellular gel self-sets in the joint and acts as a three-dimensional matrix, recruiting the patient's own progenitor cells to support cartilage repair over the following months. Because it is not a one-size-fits-all option, careful patient selection is central to achieving meaningful benefit.

Who Is Suitable?

ChondroFiller injection may suit adults with osteoarthritis or localised joint wear, particularly where the surrounding cartilage retains reasonable structural integrity. The knee and ankle are common treatment sites, though the procedure has also been applied to the hip, thumb base, and other smaller joints. There is no fixed age cut-off, though clinical experience suggests that younger adults with a shorter history of degeneration and preserved joint architecture tend to respond more favourably. Maintaining a healthy body weight reduces joint load and is associated with better outcomes. Suitability is determined by a thorough clinical examination together with imaging — typically MRI — to map the defect and assess the surrounding tissue. Benefits vary and cannot be guaranteed.

When Is It Not Recommended?

The ChondroFiller injection is not appropriate for everyone. People with advanced, widespread osteoarthritis involving the full joint surface are generally not good candidates; this is a localised regenerative scaffold, not a treatment for end-stage disease, and it does not cure or reverse arthritis. Joints that are significantly unstable, malaligned, or restricted by scar tissue may also limit the chance of a favourable result, as the mechanical environment needs to be conducive to repair. The injection is usually considered once simpler conservative measures — physiotherapy, targeted exercise, weight management — have not provided adequate relief.

The ChondroFiller Injection and the Liquid Cartilage Surgical Pathway

It is worth understanding that ChondroFiller (the CE-marked device) can be delivered in two distinct ways, and the choice depends on the patient's clinical picture. The non-surgical ChondroFiller injection, described throughout this article, uses ultrasound guidance to place the collagen scaffold in accessible joints on an outpatient basis. This is appropriate for patients who prefer to avoid surgery, have smaller or accessible defects, or are not fit for an anaesthetic.

For patients with larger cartilage defects, load-bearing joints requiring precise preparation, or where mesenchymal stem cells (MSCs) are being incorporated, the Liquid Cartilage surgical pathway is an alternative. Liquid Cartilage is Professor Paul Y. F. Lee's keyhole (arthroscopic) surgical protocol — it delivers the ChondroFiller scaffold under dry arthroscopic conditions, combined with biological adjuncts such as platelet-rich fibrin, platelet-rich plasma, and where indicated the patient's own MSCs from bone-marrow concentrate or micro-fragmented fat. Liquid Cartilage is genuine surgery requiring a theatre, anaesthetic, and a structured rehabilitation period; it is not an injection. A specialist assessment determines which pathway — injection or surgery — is most appropriate for a given patient.

What the Evidence Shows

For patients who meet the selection criteria, published experience with the ChondroFiller scaffold is encouraging. A 2023 study examining the use of acellular collagen matrix in thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain and grip strength (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U., 2023. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage). Retrospective reviews across knee and hip applications similarly report high patient satisfaction. Response varies between individuals, which is precisely why thorough pre-procedure assessment matters.

What Clinicians Keep in Mind

A careful evaluation — combining clinical examination, joint-specific history, and MRI — helps confirm whether the injection is likely to be beneficial and rules out patients for whom it would not be appropriate. The procedure itself is straightforward: a non-surgical, ultrasound-guided injection of the acellular collagen gel into the joint, with no cell harvesting required. Setting realistic expectations is an integral part of the consultation. Patients should understand that the injection is a joint-preservation measure, not a guarantee of symptom resolution, and that some months are typically required before the scaffold fully integrates and clinical benefit becomes apparent.

Conclusion

The ChondroFiller injection is a non-surgical option that may benefit adults with osteoarthritis or localised joint wear where the surrounding cartilage environment is reasonably intact. It is not a cure and is not suited to advanced, widespread disease. With careful patient selection, thorough imaging assessment, and clear expectation-setting, clinicians can identify those most likely to benefit. For patients whose defects are larger or whose presentation points toward a surgical approach, the Liquid Cartilage keyhole surgical protocol offers a distinct and more comprehensive pathway. For individual advice tailored to your joint and circumstances, a consultation with a specialist in cartilage preservation is the appropriate starting point. The London Cartilage Clinic at Harley Street offers such assessments for both the ChondroFiller injection and the Liquid Cartilage surgical pathway.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.